Haemonetics Corp (HAE) financials
Haemonetics revenue and earnings by year
Haemonetics's revenue was $1.33 billion in the fiscal year to March 28, 2026, down 2.0% from the year before. Net income was $97.3 million, 7.3% of revenue. Since the fiscal year to April 1, 2017, revenue has grown 4.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Mar 2026 | Mar 2025 | Mar 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.33 | 1.36 | 1.31 | 1.17 | 0.99 | 0.87 | 0.99 | 0.97 | 0.90 | 0.89 |
| Revenue growth | -2.0% | 4.0% | 12.0% | 17.7% | 14.1% | -11.9% | 2.2% | 7.0% | 2.0% | — |
| Gross profit | 0.79 | 0.75 | 0.69 | 0.62 | 0.51 | 0.40 | 0.48 | 0.42 | 0.41 | 0.38 |
| Gross margin | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% | 49.0% | 43.2% | 45.6% | 42.7% |
| Operating income | 0.15 | 0.20 | 0.16 | 0.16 | 0.08 | 0.09 | 0.10 | 0.08 | 0.06 | -0.02 |
| Operating margin | 11.6% | 14.6% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% |
| Net income | 0.10 | 0.17 | 0.12 | 0.12 | 0.04 | 0.08 | 0.08 | 0.06 | 0.05 | -0.03 |
| Net margin | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% |
| Diluted EPS | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.47 | $1.05 | $0.86 | -$0.50 |
| Free cash flow | 0.21 | 0.14 | 0.12 | 0.16 | 0.08 | 0.07 | 0.13 | 0.04 | 0.15 | 0.09 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open HAE in Markets.
How Haemonetics makes money
Revenue by segment in the quarter to June 27, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Apheresis | $191M | 56.4% |
| Med Surg | $148M | 43.6% |
See also: HAE valuation and P/E history · HAE returns
No forecast, no recommendation. This page describes Haemonetics Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.